Patent SG-11201810509P-A (SG)
Title: Anti-pd-l1 antibodies
Inventor: CAMPBELL JAMIE
IPC: A61K39/395
Filed: 2017-06-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION ---_. (19) World Intellectual Property 1111111101111 0 11101 HOE 010 1111 1 0 01 OH 0101101110111101101111011111101111 Organization International Bureau l i (10) International Publication Number (43) International Publication Date .......\"' WO 2017/220990 A9 28 December 2017 (28.12.2017) Wi PO I PCT (51) International Patent Classification: Babraham CB22 3AT (GB). GILLIES, Stephen, Douglas; A61K 38/20 (2006.01) A61K 39/395 (2006.01) 47 Swanson Lane, Carlisle, MA 01741-1044 (US). C07K 14/55 (2006.01) C07K 16/28 (2006.01) (74) Agent: LEONARD, Thomas; Kilburn & Strode LLP, 20 (21) International Application Number: Red Lion Street, London, WC1R 4PJ (GB). PCT/GB2017/051796 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 20 June 2017 (20.06.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, DZ, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (30) Priority Data: KR, 62/352,291 20 June 2016 (20.06.2016) US MG, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 15/211,504 15 July 2016 (15.07.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 1613683.0 09 August 2016 (09.08.2016) GB SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 1615224.1 07 September 2016 (07.09.2016) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1615335.5 09 September 2016 (09.09.2016) GB (84) Designated States (unless otherwise indicated, for every — 15/354,971 17 November 2016 (17.11.2016) US kind of regional protection available): ARIPO (BW, GH, 1620414.1 01 December 2016 (01.12.2016) GB GM, 1621782.0 20 December 2016 (20.12.2016) GB UG, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = 1702338.3 13 February 2017 (13.02.2017) GB TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = 1702339.1 13 February 2017 (13.02.2017) GB EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — 1703071.9 24 February 2017 (24.02.2017) GB MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 15/480,525 06 April 2017 (06.04.2017) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, — = KM, ML, MR, NE, SN, TD, TG). (71) Applicant: KYMAB LIMITED [GB/GB]; The Bennet = Building (B930), Babraham Research Campus, Cambridge Published: = CB22 3AT (GB). — with international search report (Art. 21(3)) (72) Inventors: CAMPBELL, Jamie; c/o The Bennet Build- (48) Date ing (B930), Babraham Research Campus, Babraham CB22 3AT (GB). SANDY, Nikole; c/o The Bennet Building of publication of this corrected version: 01 March 2018 (01.03.2018) = = (B930), Babraham Research Campus, Babraham CB22 (15) Information about Correction: = = = 3AT (GB). VAN KRINKS, Cassandra; c/o The Ben- see Notice of 01 March 2018 (01.03.2018) = net Building (B930), Babraham Research Campus, Babra- ham CB22 3AT (GB). ARKINSTALL, Stephen John; c/ o The Bennet Building (B930), Babraham Research Cam- pus, Babraham CB22 3AT (GB). GERMASCHEWSKI, Volker; c/o The Bennet Building (B930), Babraham Re- = = search Campus, Babraham CB22 3AT (GB). KIRBY, Ian; = c/o The Bennet Building (B930), Babraham Research Cam- - = pus, Babraham CB22 3AT (GB). KOSMAC, Miha; c/o The Bennet Building (B930), Babraham Research Campus, Babraham CB22 3AT (GB). GALLAGHER, Thomas; c/o _ The Bennet Building (B930), Babraham Research Campus, 0\ Babraham CB22 3AT (GB). DEANTONIO, Cecilia; c/o 0 The Bennet Building (B930), Babraham Research Campus, 0\ 0\ 0 ei el (54) Title: ANTI-PD-L1 ANTIBODIES IN (57) : The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity 1-1 c:::: , to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also N provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immuno- P1 cytokines.